Provided herein are methods for detecting, monitoring, diagnosing and treating respiratory-related viral infections, including SARS-CoV-2 infected individuals and subjects that are infected with or suspected of having been infected with the virus, or that have come in contact with COVID-19 suffering individuals.

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH.sub.2—SO.sub.3H)COOH or Arg-Gly-NH—CH(CH.sub.2—SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to α.sub.5β.sub.1-Integrin, α.sub.vβ.sub.3-Integrin and α.sub.vβ.sub.5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

The invention provides conjugates of cyclic peptides as ligands for cellular surface receptors, in particular, as ligands for αvβ6-integrin. The conjugates further contain effector moieties and are suitable for use as therapeutic agent, diagnostic agent, agent for imaging, targeting moiety and as biomolecular research tool. The invention specifically relates to the use of conjugates with signalling moieties or radionuclides for in-vivo addressing of αvβ6-integrin.

The present invention relates to a labeling procedure for the incorporation, in mild reaction conditions, of sensitive and thermosensitive targeting molecules into a [.sup.99mTc(N)(PNP)]-based compound suitable for a kit formulation.

Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH.sub.2—SO.sub.3H)COOH or Arg-Gly-NH—CH(CH.sub.2—SO.sub.3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.

A method of preparing a .sup.64Cu-BaBaSar-RGD.sub.2 solution is provided. The method includes lyophilizing a solution of BaBaSar-RGD.sub.2 and adding a .sup.64Cu solution to the lyophilized BaBaSar-RGD.sub.2.

A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

A compound includes at least one targeting peptide coupled to a detectable moiety. The targeting peptide binds to EDB-FN or EDA-FN and includes at least one of amino acid sequence selected from the group consisting of SEQ ID NOs: 1-30.

Fluoridated organofluoroborates comprising at least one .sup.18F atom and precursors thereto, for use in PET scanning.

The present invention relates to .sup.99mTc-maraciclatide radiopharmaceutical compositions, which are stabilised with a radioprotectant. Also described are kits for the preparation of the radiopharmaceutical compositions, as well as methods of preparing such compositions from the kit. The invention also includes methods of imaging the mammalian body using the radiopharmaceutical compositions.